Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia

Chikkappa, G.; Pasquale, Donald; Zarrabi, Mahboobeh; Weiler, Robert J.; Divakara, M.; Tsan, Min‐Fu

doi:10.1002/ajh.2830410103

Cited by 35 publications

(13 citation statements)

References 25 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRBCA is generally responsive to corticosteroid therapy but patients usually required prolonged high dose therapy or combination therapy to maintain remission26,71. Response should be monitored by measuring the absolute reticulocyte count which usually increases within 2–3 weeks of initiation of therapy while substantial improvements in the hemoglobin level can take up to a month.…”

Section: Managementmentioning

confidence: 99%

Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)

Zent

Kay

2010

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

Patients with B-chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) have a 5–10% risk of developing autoimmune complications which primarily cause cytopenia. These autoimmune cytopenias can occur at any stage of CLL and do not have independent prognostic significance. The most common autoimmune complication is autoimmune hemolytic anemia with a lower frequency of immune thrombocytopenia and pure red blood cell aplasia and only rare patients with autoimmune granulocytopenia. Autoimmune cytopenia should always be considered in the differential diagnosis of cytopenia in patients with CLL. Patients with CLL can also have more than one form of autoimmune cytopenia which can occur together with bone marrow failure. Treatment is usually effective but rarely curative for autoimmune cytopenia complicating CLL. Optimal therapy will depend on a timely and accurate diagnosis of autoimmune cytopenia and should be individualized according to the severity of the cytopenia and the presence or absence of concomitant progressive CLL requiring therapy.

show abstract

Section: Managementmentioning

confidence: 99%

Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)

Zent

Kay

2010

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

show abstract

“…As previous studies of PRCA had used CsA together with corticosteroids (241, whether CsA alone is effective has not been addressed. Chikkappa et al [5] had also successfully treated PRCA associated with B-cell chronic lymphocytic leukemia with CsA, but concomitant steroids were used as well. Moreover, the starting dose of CsA was 12 mg/kg/day in these studies, and it had been suggested that such a large dose was necessary [6].…”

Section: Pure Red Cell Aplasia Successfully Treated By Cyclosporin a mentioning

confidence: 99%

Severe erythrodermia caused by M‐CSF

Masumoto¹,

Kawada²,

Fukuda³

et al. 1994

American J Hematol

View full text Add to dashboard Cite

show abstract

“…A proportion of these patients, however, eventually require splenectomy or low-dose spleen radiation [84]. Pure red-cell aplasia (PRCA) may occasionally be associated with CLL; good treatment results have been reported with cyclosporine [85].…”

Section: Patients With Cytopenias Due To Immune Mechanismmentioning

confidence: 99%

B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy

Montserrat¹,

Bosch²,

Rozmán³

1997

Annals of Oncology

View full text Add to dashboard Cite

SummaryB-cell chronic lymphocytic leukemia (CLL) is a highly common form of leukemia characterized by the accumulation of longlived, functionally inactive, mature appearing neoplastic B lymphocytes. In addition, immune disturbances such as hypogammaglobulinemia and autoimmune phenomena (particularly, autoimmune hemolytic anemia) are frequently found in CLL patients [1][2]. The etiology of CLL is unknown. In contrast with other leukemias, there is no relationship between CLL and exposure to radiation or other cytotoxic agents. A genetic basis is highly likely since there are differences in the incidence of CLL in different countries (e.g., CLL accounts for 30%-40% of all the leukemias in Western countries as compared to 5%-10% in Asian countries) and the risk of contracting CLL is higher among persons with first-degree relatives with the disease [3].Because the incidence of CLL increases with age and the longer life expectancy of the general population, the age of patients at diagnosis is increasing. The median age at diagnosis is now about 70 years, with only one-third of the patients being less than 60 years of age. In the majority of the series, males predominate over females in a proportion of 1.5/1. The prognosis of patients with CLL is variable. However, clinical stages and other prognostic factors allow the individual risk of each patient to be assessed very accurately, which is useful for making treatment decisions.In the past two decades, significant progress has been made in CLL [4][5][6][7][8][9][10]. This review summarizes recent advances in the biology, diagnosis, and therapy of CLL.

show abstract

Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia

Cited by 35 publications

References 25 publications

Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)

Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL)

Severe erythrodermia caused by M‐CSF

B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy

Contact Info

Product

Resources

About